Clinical Trial News and Research

RSS

Study to explore whether early depression treatment can reduce risk of heart disease

Jesse Stewart, Ph.D., assistant professor of psychology in the School of Science at Indiana University-Purdue University Indianapolis and an Indiana University Center for Aging Research affiliated scientist, has received a $110,000 grant from the American Heart Association to explore whether treatment of depression before one experiences a heart attack can reduce the likelihood of future heart disease.

25 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular Therapeutics, Ltd today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme.

25 May 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues.

25 May 2011

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Abbott today announced it has received U.S. Food and Drug Administration approval for the XIENCE nano Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels.

25 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute has awarded Altor a Small Business Innovation Research Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor's efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Viewpoints: IPAB debate; Medicare flap continues; WSJ on VT single payer

While I applaud Ryan for getting the conversation started, I cannot support his specific plan — and therefore will vote "no" on his budget. Why can't I go along with the Ryan Medicare plan?

23 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its DESyne Drug Eluting Coronary Stent System for the treatment of coronary artery disease.

23 May 2011

Archimedes launches new web interface, ARCHeS Innovator

Archimedes Inc., a healthcare modeling company, today announced the launch of a new web interface, ARCHeS Innovator, which will give health experts direct access to many of the features of the Archimedes Model.

23 May 2011

New hybrid OR at Loyola equipped with advanced fluoroscopy equipment

Loyola University Medical Center has opened a hybrid operating room that combines the imaging capabilities of a cardiac catheterization lab with the sterile environment of a conventional operating room (OR).

23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Stanford University develops stress-shielding device to reduce surgical scarring

Researchers at Stanford University have developed a special wound dressing that they report was able to significantly reduce scar tissue caused by incisions.

23 May 2011

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.

21 May 2011

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.

From Medtronic 21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Clinical Trial News and Research

Study to explore whether early depression treatment can reduce risk of heart disease

Positive interim results from new bladder cancer therapy trial

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Viewpoints: IPAB debate; Medicare flap continues; WSJ on VT single payer

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Archimedes launches new web interface, ARCHeS Innovator

New hybrid OR at Loyola equipped with advanced fluoroscopy equipment

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Stanford University develops stress-shielding device to reduce surgical scarring

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer